key: cord-0289083-oini75ax
authors: Afsar, Mohammad; Narayan, Rohan; Akhtar, Md Noor; Rahil, Huma; Eswarappa, Sandeep M; Tripathi, Shashank; Hussain, Tanweer
title: Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2
date: 2021-11-03
journal: bioRxiv
DOI: 10.1101/2021.11.02.466951
sha: b80394dce6c4d4495fc793fac889ee4bb62c0eae
doc_id: 289083
cord_uid: oini75ax

The SARS-Cov-2 non-structural protein 1 (Nsp1) contains an N-terminal domain and C-terminal helices connected by a short linker region. The C-terminal helices of Nsp1 (Nsp1-C-ter) from SARS-Cov-2 bind in the mRNA entry channel of the 40S ribosomal subunit and block the entry of mRNAs thereby shutting down host protein synthesis. Nsp1 suppresses the host immune function and is vital for viral replication. Hence, Nsp1 appears to be an attractive target for therapeutics. In this study, we have in silico screened Food and Drug Administration (FDA)-approved drugs against Nsp1-C-ter and find that montelukast sodium hydrate binds to Nsp1-C-ter with a binding affinity (KD) of 10.8±0.2 μM in vitro and forms a stable complex with it in simulation runs with a binding energy of −76.71±8.95 kJ/mol. The drug also rescues the inhibitory effect of Nsp1 in host protein synthesis as demonstrated by the expression of firefly luciferase reporter gene in cells. Importantly, montelukast sodium hydrate demonstrates antiviral activity against SARS-CoV-2 with reduced viral replication in HEK cells expressing ACE2 and Vero-E6 cells. We therefore propose montelukast sodium hydrate may help in combatting SARS-CoV-2 infection.

SARS-CoV-2, the causative agent of severe coronavirus disease-19 pandemic, is an 52 enveloped positive-strand RNA-containing virus and belongs to the beta coronavirus family 53 (V'Kovski et al., 2021) . The virus contains nearly 30kb RNA genome with 5'-cap and 3'-poly-A tail 54 (Finkel et al., 2021; V'Kovski et al., 2021) . Upon entry into the host cell, the SARS-CoV-2 genome 55

encodes for fourteen open reading frames (ORFs). The ORF1a and ORF1ab encode for two 56 polyproteins, which are later auto-proteolytically cleaved into sixteen proteins, namely Nsp1-57

Nsp16. 58 59

The cryo-electron microscopy (cryo-EM) structures of ribosomes from Nsp1-transfected human 60

HEK293T cells indicate the binding of Nsp1 with the 40S and 80S ribosomal subunits (Schubert et 61 al., 2020; Thoms et al., 2020; Tidu et al., 2020; Vankadari et al., 2020) ( Figure 1A ). Nsp1 contains 62 180 amino acids with N-terminal (1-127 amino acids) and C-terminal (148-180 amino acids) 63 structured regions connected by a loop region of about 20 amino acids (Schubert et al., 2020; 64 Thoms et al., 2020) ( Figure 1B ). This C-terminal region of Nsp1 (Nsp1-C-ter) contains two helices 65 that harbours a conserved positively charged motif (KH-X 5 -R/Y/Q-X 4 -R). The deposition of 66 positive charge towards one edge of these helices enhances their ability to bind the helix h18 of 18S 67 rRNA. The other side of C-terminal helices interact with ribosomal proteins uS3 and uS5 in mRNA 68 entry tunnel of 40S (Schubert et al., 2020; Thoms et al., 2020) (Figure 1A , zoomed view). These 69 interactions enable Nsp1-C-ter bind deep into the mRNA entry tunnel and prevent the binding of 70 mRNAs thereby inhibiting host protein synthesis (Schubert et al., 2020; Thoms et al., 2020; Tidu et 71 al., 2020) . Thus, Nsp1 helps in hijacking the host translational machinery (Yuan et al., 2020) and the 72 cells are unable to mount innate immune response to counter the viral infection (Narayanan et al., 73 2008) . Mutating the positively charged residues K164 and H165 in Nsp1-C-ter to alanines leads to a 74 decrease in binding of Nsp1 with the ribosome and failure to inhibit host protein synthesis 75 (Schubert et al., 2020; Thoms et al., 2020; Tidu et al., 2020) . 76 77 Nsp1 is a highly conserved protein and less than 3% of the SARS-CoV-2 genomic sequences 78 analysed showed mutation in Nsp1 (Min et al., 2020) . Further, the Nsp1-C-ter showed a much 79 reduced frequency of mutations (Min et al., 2020) . The crucial role of the Nsp1 in inhibiting host 80 gene expression, suppression of host immune response (Narayanan et al., 2008) and, notably, the 81 reduced mutation frequency in Nsp1-C-ter across global SARS-CoV-2 genomes (Min et al., 2020) 82 advocate targeting Nsp1 for therapeutics. In this study, we have employed computational, 83 bacterial cells of 0.6 O.D., the cultures were then transferred at 16℃ at 120 rpm, and the expression 119 of pET28a-His-Nsp1 and pET28a-His-Nsp1∆40 were induced by adding 1 mM of Isopropyl β-d-1-120 thiogalactopyranoside (IPTG) and allowed to grow for 18 hours. The bacterial cells were then 121 harvested at 6000 rpm and resuspended in buffer A (50 mM HEPES-KOH pH 7.6, 500 mM KCl, 5 122 mM MgCl 2 , 5% Glycerol). The cells were then lysed by sonication at 18% amplitude and 10 sec 123 on/off cycles for 10 min. The lysate was then subjected to centrifugation at 12000 rpm for 30 124 minutes to remove the cell debris. The clear supernatant was then loaded on the Ni-NTA beads 125 (Qiagen) and incubated for 3 hours, and beads were then washed using buffer A. The bound protein 126 was then eluted with buffer A supplemented with 300 mM imidazole, and purity was analysed on 127 SDS-PAGE. The fractions which are containing the corresponding protein were concentrated and 128 subjected to size exclusion chromatography on Superdex 200 increase 10/300 column in buffer B 129 (50 mM HEPES-KOH pH 7.6, 150 mM KCl, 5 mM MgCl 2 , 2% Glycerol and 2 mM DTT). The 130 pure protein fractions were pooled and concentrated between 2-8 mg/ml and stored in -80 ℃ for 131 further use. 132 133 Drug-binding assays: 134

To identify the kinetic behaviour of the top selected compounds, we performed the label-free 136 binding kinetics of the protein and ligands by using the bio-layer interferometry. The binding of 137 ligand molecule on protein immobilized sensors induce change in the optical interference pattern of 138 white light and is measured in nm. The Ni-NTA sensors were first activated by incubating in 10 139 mM Phosphate buffer saline for 10 min. After sensor activation, these sensors were then transferred 140 to Buffer B. 2 µM of each protein was loaded on the Ni-NTA sensor and achieved a binding 141 response of around 1 nm. The initial screening of the compounds was performed at 20 µM for all 142 the in silico selected top hits. The drug molecules that showed binding response of more than 0.2 143 nm was selected for further kinetic experiments. Subsequently, the kinetic experiments were 144 performed by incubating the protein-bound sensors with the increasing ligand concentration (0-25 145 µM) and binding was monitored. The data for control sensors (without protein) for each ligand 146 concentration were also collected and subtracted from the response of proteins-bound sensors. The 147 subtracted data was then analysed by fitting the 1:1 stoichiometric ratio for association and 148 dissociation by applying the global fitting. Three independent experiments were performed to 149 evaluate the steady-state kinetics and calculated K D values. 150 151

In silico identified potential hits were then subjected to evaluate the binding with the His-Nsp1 and 153

His-Nsp1∆40 of SARS-CoV-2 protein. 2 µM of each protein was subjected to determine the 154 melting temperature (Tm) in buffer B. The temperature scans were ranges from 20-90℃ with the 155 1℃/min ramp size using Prometheus NT.48 NanoTemper. After successfully determining the 156 melting temperature for individual proteins alone, we determined the ΔTm in the presence of drug 157 molecules (10 µM) to identify the binding of the drug molecules. The top hits were selected for 158 further evaluation in a change of the Tm by incubating with different concentrations of ligand (0-16 159 µM). The data was analysed by using ThermControl software. 160 161

The molecular dynamic simulations of FDA-approved drugs in complex with Nsp1-C-ter were 163 selected based on the top binding score using BLI and NanoDSF. The final docked complexes were 164 then prepared for molecular dynamics simulation studies. The systems for molecular dynamics 165 studies were prepared for the Nsp1-C-ter alone and their complex with top hits using the Desmond 166 v4.1implemented in Schrodinger-Maestro v11, where steric clashes and side-chain bumps were 167 fixed. These prepared structures were then optimized by GROMOS96 54a7 force field (Schmid et 168 al., 2011) and simple point charge water model was used to add the solvent molecules in the 169 dodecahedron box with a distance of 1Å from the surface of the protein. Additionally, four sodium 170 ions were added to neutralize the system. The following energy minimization was performed for all 171 the systems with 5000 steps of steepest descent and conjugate gradient algorithms with threshold 172 energy of 100 kCal/mol. The systems were then equilibrated in two phases, first is the isothermal-173 isochoric equilibration, where the constant number, volume, and temperature (NVT) was 174 equilibrated for 100 picoseconds (ps), and the temperature of the system was monitored for all 175 constants. In the second phase, the isothermal-isobaric equilibration was performed where the 176 number of particles, pressure, and temperature (NPT) was equilibrated for 100 ps. After successful 177 equilibration of the system, the final molecular dynamic runs were performed for 200 nanoseconds 178 (ns) in three replicas with 2 femtoseconds of time steps. The root mean square deviation (RMSD), 179 root mean square fluctuation (RMSF), and three-dimensional coordinates for all atoms of protein 180 and ligands were extracted to analyse the molecular dynamics runs. The two subsequent 100 ns runs from MD simulations were further subjected to perform the MM-186 PBSA by using the python script (mmpbsa.py) to calculate the binding energy of the two drugs. transfection, and luciferase activity was measured by using the Luciferase Reporter assay system 203 (Promega Corporation) in the GLoMax Explorer system (Promega Corporation). 204

We further moved to check the expression level of FLuc and Glyceraldehyde 3-phosphate 205 dehydrogenase (GAPDH). We isolated the total RNA from all conditions using the TRIzol by 206 following the user manual protocol. Then we used 0.5 µg of total RNA to amplify the mRNA in the 207 form of cDNA by using the RevertAid First Strand cDNA synthesis kit using manufacturer's 208 protocol. The amplified product was then used as template to amplify the FLuc and GAPDH gene 209 in the presence of appropriate primers as mentioned in Table S1 . The relative Ct values were 210 monitored in the three replicates and relative fold change in expression was calculated. The 211 significance of the data was monitored by applying the unpaired t-test through assuming Gaussian 212 distribution parametric test by defining the statistical significance P<0.5. 213 To evaluate the total viral copy number, we isolated the RNA from SARS CoV-2 infected cells 214 using TRIzol as per manufacturer's instructions, and equal amount of RNA used to determine the 215 viral load using AgPath-ID™ One-Step RT-PCR kit (AM1005, Applied Biosystems). The primers 216 and probes against SARS CoV-2 N-1 gene used are mentioned in Supplementary table S1. A 217 standard curve was made using SARS CoV-2 genomic RNA standards, which was used to 218 determine viral copy number from ct values. 219 220

The following cell lines were used in this study, namely HEK 293T cells (CRL-1573 Since repurposing a drug is a quicker way to identify an effective treatment, we screened FDA-284 approved drugs against Nsp1-C-ter (148-180 amino acids) which binds in the mRNA channel 285 ( Figure 1C ). The drugs docked to a small region of Nsp1-C-ter consisting of residues (P153, F157, 286 N160, K164, H165, and R171) which coincides with its ribosome-binding interface ( Figure 1C) . 287

The residues in Nsp1-C-ter involved in binding drugs show minimal mutations in worldwide 288 deposited 4,440,705 sequences of SARS-CoV-2 genome in GISAID database ( Figure 1D ). We 289 identified top hits with at least three hydrogen bonds (H-bonds) near the ribosome binding site of 290 Nsp1-C-ter (Table 1) . Further, the clash that the drugs may have against the ribosome in its bound 291 form with Nsp1-C-ter was also analyzed. Montelukast sodium hydrate (hereafter referred to as 292 montelukast) and saquinavir mesylate (hereafter referred to as saquinavir) showed high clash scores 293 (Table 1) . Montelukast is regularly used to make breathing easier in asthma (Paggiaro and Bacci, 294 2011), while saquinavir is an anti-retroviral drug used in the treatment of human immunodeficiency 295 virus (HIV) (Khan et al., 2021) . 296 297 Next, all twelve drugs were tested in vitro for their ability to bind to Nsp1. The purified proteins, 298

i.e., full-length Nsp1 and C-terminal helices truncated Nsp1 (Nsp1∆40) proteins, were loaded on the 299

Ni-NTA sensors in BLI, and the compounds were screened to determine its binding to these 300 proteins. We found that montelukast and saquinavir show binding to Nsp1 ( Figure 1E ) but not with 301 Nsp1∆40 ( Figure 1F ). This indicates that montelukast and saquinavir bind to Nsp1-C-ter. The rest 302 of the compounds does not show binding with Nsp1 or with Nsp1∆40 ( Figure 1E Since repurposing a drug is a quicker way to identify an effective treatment, we screened FDA-380 approved drugs against the Nsp1-C-ter and found montelukast as potential drugs against it. 381

Montelukast is a leukotriene receptor antagonist and repurposing montelukast for tackling cytokine 382 storms in COVID-19 patients has been suggested (Sanghai and Tranmer, 2020) and hospitalized 383 COVID-19 patients that were given montelukast had significantly fewer events of clinical 384 deterioration (Khan et al., 2021) . Montelukast also appears as a hit against the SARS-CoV-2 main 385 protease, (M pro ) protease, in computational studies (Abu-Saleh et al., 2020; Sharma et al., 2021) . Viruses employ different strategies to shutdown host translation machinery. In SARS-CoV-2, Nsp1 390 inhibits translation by binding to the mRNA channel. Here, we show that montelukast binds to 391 Nsp1, rescues the Nsp1-mediated protein translation inhibition and has antiviral activity against 392 SARS-CoV-2. The rescue of shutdown of host protein synthesis machinery by montelukast seems 393 to contribute towards the antiviral activity of the drug; however, further experiments would be 394 essential to figure out detailed mechanism of its antiviral activity. Overall, our study identifies C-395 terminal region of Nsp1 as a druggable target and montelukast as a potential antiviral drug against 396 SARS-CoV-2 infection that may help in combatting the COVID-19 pandemic. 397 Schubert, K., Karousis, E.D., Jomaa, A., Scaiola, A., Echeverria, B., Gurzeler, L.A., Leibundgut, 510 M., Thiel, V., Muhlemann, O., and Ban, N. (2020) . Kovski, P., Kratzel, A., Steiner, S., Stalder, H., and Thiel, V. (2021) Error bars represent standard deviation of three replicates in (A) and (B). The significance of the 614 data was monitored by applying the unpaired t-test through assuming Gaussian distribution 615 parametric test by defining the statistical significance. **P < 0.01; ***P < 0.001; ****P < 0.0001. 616

The error bars represent the standard deviation. 

0001; ns-not significant, using one-way ANOVA with 632

Dunnett's multiple comparison test. Error bars represent standard deviation

Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS

Sandeep M Eswarappa

Cells were treated in triplicates with increasing concentrations of montelukast or saquinavir as 697 indicated, and cytotoxicity of the drugs was tested 48hr later by Alamar Blue assay. Data shows 698 percentage toxicity of drugs compared to cell control in A) HEK-ACE2 and B) Vero E6 cells

0001; ns -not significant, using one-way ANOVA with 700

Dunnett's multiple comparison test. Error bars represent standard deviation

Figure 4 figure supplement 2. Saquinavir did not show significant antiviral activity against 706 SARS-CoV-2

HEK ACE2 cells were pre-treated with 5 or 10 µM saquinavir and infected with 0.1 MOI SARS 708

Viral RNA copy number from infected cells was 710 quantified by qRT PCR, and infectious virus titer from cell culture supernatants by plaque assay, 711 shown in (B) and (C) respectively. Vero E6 cells were pre-treated with 5 or 10 µM saquinavir and 712 infected with 0.001 MOI SARS CoV-2 for 48hr. (D) Virus spike protein expression by western blot 713 analysis, with relative density of bands. (E) Viral RNA copy number from infected cells was 714 quantified by qRT PCR and (F)

0001; ns -not significant, using one-way ANOVA with 717

Dunnett's multiple comparison test. Error bars represent standard deviation